Analysts expect Insys Therapeutics, Inc. (NASDAQ:INSY) to announce sales of $36.89 million for the current quarter, according to Zacks. Three analysts have provided estimates for Insys Therapeutics’ earnings, with estimates ranging from $35.43 million to $38.25 million. Insys Therapeutics reported sales of $67.12 million in the same quarter last year, which indicates a negative year-over-year growth rate of 45%. The company is scheduled to report its next quarterly earnings report on Wednesday, August 2nd.

According to Zacks, analysts expect that Insys Therapeutics will report full-year sales of $36.89 million for the current fiscal year, with estimates ranging from $140.59 million to $158.44 million. For the next financial year, analysts anticipate that the company will report sales of $180.33 million per share, with estimates ranging from $167.00 million to $187.86 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Insys Therapeutics.

Insys Therapeutics (NASDAQ:INSY) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.09) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. The company had revenue of $35.92 million for the quarter, compared to the consensus estimate of $37.78 million. Insys Therapeutics had a negative net margin of 2.64% and a negative return on equity of 0.97%. The firm’s revenue was down 40.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.11 EPS.

Several brokerages have recently issued reports on INSY. Piper Jaffray Companies cut shares of Insys Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $20.00 to $10.00 in a research report on Wednesday, May 10th. BidaskClub upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 8th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a research note on Thursday, April 6th. Zacks Investment Research lowered shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 6th. Finally, Royal Bank Of Canada set a $16.00 price target on shares of Insys Therapeutics and gave the company a “buy” rating in a research note on Monday, March 27th. Two analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $13.75.

TRADEMARK VIOLATION WARNING: “Insys Therapeutics, Inc. (NASDAQ:INSY) Expected to Post Quarterly Sales of $36.89 Million” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/20/insys-therapeutics-inc-nasdaqinsy-expected-to-post-quarterly-sales-of-36-89-million.html.

Insys Therapeutics (NASDAQ:INSY) traded up 0.08% on Thursday, reaching $12.70. 53,572 shares of the company’s stock were exchanged. Insys Therapeutics has a one year low of $8.70 and a one year high of $19.96. The stock’s market cap is $915.99 million. The firm has a 50 day moving average of $12.60 and a 200-day moving average of $11.39.

In other news, Director Rohit Vishnoi acquired 4,000 shares of the firm’s stock in a transaction dated Thursday, June 1st. The stock was acquired at an average cost of $14.14 per share, with a total value of $56,560.00. Following the completion of the acquisition, the director now owns 4,000 shares of the company’s stock, valued at $56,560. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Steven J. Meyer acquired 8,000 shares of the firm’s stock in a transaction dated Thursday, May 18th. The stock was purchased at an average cost of $12.21 per share, with a total value of $97,680.00. Following the completion of the acquisition, the director now directly owns 52,083 shares of the company’s stock, valued at approximately $635,933.43. The disclosure for this purchase can be found here. Insiders bought 21,900 shares of company stock valued at $268,090 over the last three months. Corporate insiders own 67.90% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Credit Agricole S A increased its stake in Insys Therapeutics by 20.0% in the first quarter. Credit Agricole S A now owns 374,400 shares of the specialty pharmaceutical company’s stock valued at $3,935,000 after buying an additional 62,400 shares during the last quarter. Alliancebernstein L.P. increased its stake in Insys Therapeutics by 18.0% in the first quarter. Alliancebernstein L.P. now owns 61,620 shares of the specialty pharmaceutical company’s stock valued at $648,000 after buying an additional 9,400 shares during the last quarter. American International Group Inc. increased its stake in Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock valued at $152,000 after buying an additional 953 shares during the last quarter. Schroder Investment Management Group increased its stake in Insys Therapeutics by 36.2% in the first quarter. Schroder Investment Management Group now owns 76,894 shares of the specialty pharmaceutical company’s stock valued at $845,000 after buying an additional 20,439 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Insys Therapeutics by 37.9% in the first quarter. JPMorgan Chase & Co. now owns 45,694 shares of the specialty pharmaceutical company’s stock valued at $480,000 after buying an additional 12,561 shares during the last quarter. 28.19% of the stock is owned by institutional investors and hedge funds.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get a free copy of the Zacks research report on Insys Therapeutics (INSY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.